ZTlido Performance

The analytical dashboard provides a comprehensive overview of product performance and market dynamics, primarily for ZTlido, as indicated by the active selection in the left-hand product navigation panel. This navigation features radio buttons for "ZTlido®" and "Elyxyb™", with ZTlido currently highlighted. A "Weekly TRx Trend (QTD)" line chart, situated in the top-left, illustrates quantitative data across three categories: "Com + Med" (e.g., 75 on 3/30), "Non-Com" (e.g., 28 on 3/30), and "Total" (reaching 103 on 3/30) from January 5th to March 30th. Adjacent to this, a "QTD TRx" section presents key performance indicators for ZTlido, including 1013 actual TRx, a QTD Goal of 650, and an impressive 156% attainment for both QTD and QTR. Directly below these KPIs, a "Weekly TRx vs Goal (Cumulative)" bar and line chart visually tracks cumulative weekly goals against actual TRx, with the actual TRx (green line) consistently exceeding the cumulative goal (blue bars), culminating in a 156% attainment on March 30th. The middle row begins with a "Market Overview (Multiverse)" panel, featuring a "Last 13 Weeks" dropdown filter, which displays market volumes for "ZTlido" at 3.75k (+4.8%), "Gabapentin" at 10.50k (+1.2%), and "Lidocaine" at 8.40k (-1.8%), with sales data current as of March 28, 2025. Following this, the "Top 10 Writers (Multiverse)" panel is a horizontal bar chart detailing "TRx Volume" for ten healthcare professionals, led by Dr. Albert Schweitzer with 185 TRx, down to Dr. Barry Marshall with 75 TRx. Concurrently, the "Top 10 Decliners (Targets)" panel identifies ten professionals exhibiting decreases, comparing "ZTlido" (red bars) and "Lidocaine" (orange bars) performance. For instance, Dr. Joseph Lister shows a -45 decline for ZTlido and a +25 change for Lidocaine, indicating varied shifts in product usage among targets. The bottom row commences with a table outlining call activity metrics for "ZTlido", showing an "Expected QTR" of 180, "Expected QTD" of 60, "Actual Calls QTD" of 52, and a "CPA % QTD" of 87%. Next, a multi-column table presents "Steps" for both ZTlido and Elyxyb, detailing "HCP" engagement percentages and absolute numbers. "Step 1" shows ZTlido at 85% and 85 HCPs, while Elyxyb is at 72% and 72 HCPs; "Step 2" reflects ZTlido at 80% and 80 HCPs, and Elyxyb at 64% and 64 HCPs, with an indication of further steps via a scrollable area. The dashboard concludes with two prominent metrics in the bottom-right panel: a large value of "145" associated with ZTlido, and an "Avg. Calls Per Day" of 3.7, accompanied by an informative "i" icon, suggesting additional context is available. The overall layout efficiently organizes diverse operational and strategic data points to provide actionable insights into product performance and prescriber engagement.